- After 25 years of clinical practice in methylation medicine, I can tell you the same mistakes recur. Not because people aren't trying. But because the information available online is either dangerously oversimplified, biochemically incorrect, or written by someone who has never had to sit with a patient experiencing the consequences of getting this wrong. These five mistakes are the ones I see most frequently — in patients who come to me after years of trial and error, in practitioners who are doing their best with incomplete training, and in the endless lists of protocols that circulate on MTHFR forums and Facebook groups. If you recognise yourself in any of these, you are not alone. And more importantly, there is a clear, mechanistically sound way to do this better. Mistake 1: Taking Folic Acid Instead of Methylfolate This is the most common — and potentially the most consequential — mistake in MTHFR management. It seems logical on the surface. MTHFR affects folate metabolism. Folic acid is a form of folate. Therefore, take folic acid. The problem is that folic acid is not folate. It is a synthetic, oxidised form of folate that does not occur in nature and requires a multi-step enzymatic conversion before your body can use it. Here is the biochemical reality: Folic acid must first be converted to dihydrofolate (DHF), then to tetrahydrofolate (THF), and finally — via MTHFR — to 5-methyltetrahydrofolate (5-MTHF), the active form your cells require. The critical bottleneck is an enzyme called DHFR (dihydrofolate reductase), which performs the first conversion step. DHFR has notoriously low activity in humans — far lower than in most other mammals. Even in people without MTHFR variants, this conversion is sluggish. In people with MTHFR variants, the entire downstream pathway is already compromised. The result: unmetabolised folic acid (UMFA) accumulates in the bloodstream. This is not a theoretical concern. Research has identified UMFA as clinically problematic for several reasons:

This is probably the most common question I receive. "I have C677T. My friend has A1298C. We've both been told we have MTHFR. But our symptoms are completely different and our doctors gave us the same advice. Why?" The answer lies in understanding what each variant actually does at the biochemical level and why treating MTHFR as a single diagnosis is one of the most significant oversimplifications in functional medicine today. Let me walk you through it properly. First — What Is MTHFR Actually Doing? MTHFR stands for methylenetetrahydrofolate reductase, an enzyme that performs one of the most critical steps in your folate metabolism pathway. Its job is specific: it converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF) , the active form of folate that your body can actually use. Why does this matter? Because 5-MTHF has one primary downstream job of enormous clinical significance: it donates a methyl group to convert homocysteine back into methionine. Methionine then becomes SAM (S-adenosylmethionine), your body's universal methyl donor, involved in over 200 enzymatic reactions, including: - DNA methylation (gene expression regulation) - Neurotransmitter synthesis (dopamine, serotonin, noradrenaline) - Myelin synthesis (neurological integrity) - Phosphatidylcholine production (cell membrane health) - Glutathione production (your master antioxidant) When the MTHFR function is compromised, this entire downstream cascade is affected. But how it is compromised depends entirely on which variant you carry, and that is where C677T and A1298C diverge significantly. The C677T Variant: The Thermolabile Problem What it is: C677T is a single-nucleotide polymorphism, a substitution of cytosine (C) for thymine (T) at position 677 of the MTHFR gene. This causes an amino acid change from alanine to valine in the MTHFR enzyme protein. What it does: This structural change makes the MTHFR enzyme thermolabile, meaning it becomes unstable and loses activity at normal body temperature. The enzyme essentially misfolds under physiological conditions.

This is the first thing I'd love you to do when you join. Reply below and tell us: 1. Your variant: C677T, A1298C, compound heterozygous, or not yet tested? 2. What brought you here: what's your biggest question or health concern right now? 3. One thing you're hoping to get from this community 4. Every reply gets a personal response from me. This is not a number on a member's list; you are a person with a real health story, and it matters. I'll go first 👇 As a physician, I became interested in methylation after observing several patients who did not improve with standard protocols. I saw a gap in how I cared for patients. This prompted me to study genomics and nutrigenomics, with a focus on MTHFR and how minor genetic variations affect health. As I learned about MTHFR's clinical relevance, similarities between my patients, my personal medical history, and the condition led me to undergo genetic testing. I found that I am heterozygous for the MTHFR 1298 T>C variant. This underscored the importance of genetics in clinical practice and changed the way I support patients, especially those who do not respond to standard protocols. I now ensure my diet includes ample folate-rich foods and, as needed, supplements. After 25 years in practice, I am convinced that identifying key genetic factors is essential for effective patient care, helping me focus on meaningful interventions and avoid unnecessary complexity.